Clinical Trial Update: Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies [Phase 1]

View source ↗

Summary

Phase I trial update on subcutaneous TQB2825 for CD20-positive hematologic malignancies; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• TQB2825

Snippet

Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Conditions: CD20-positive Hematological Malignancies | Phase 1 | Status: NOT_YET_RECRUITING